Myfembree for moderate-to-severe endometriosis pain: Potential for adolescents

A nationwide recall has been issued for ibrexafungerp products after a potential cross contamination with a non-antibacterial ß-lactam drug substance was discovered.

In this episode of Pap Talk, Contemporary OB/GYN® Associate Editor Lindsey Carr sat down with Jessica Shim, MD, an attending at in the Division of Gynecology, Department of Surgery, Boston Children’s Hospital; Harvard Medical School Boston, Massachusetts, to discuss Myfembree (relugolix, estradiol, and norethindrone acetate tablets; Myovant Sciences, Pfizer) and its possible approval in May 2022.

If approved, cefepime-taniborbactam will provide treatment against complicated urinary tract infections in adults.

In this episode of Pap Talk, Contemporary OB/GYN® sat down with Maneesh Jain, CEO of Mirvie, and Michal Elovitz, MD, chief medical advisor at Mirvie, a new RNA platform that is able to predict pregnancy complications by revealing the biology of each pregnancy. They discussed recently published data regarding the platform's ability to predict preeclampsia and preterm birth.

Zuranolone (SAGE-217; SAGE Therapeutics) has been granted priority review for treatment against postpartum depression and major depressive disorder symptoms.

Researchers have developed a method of administrating methotrexate through polymersomes for improved efficacy when treating ectopic pregnancy.